Navigation Links
Cystic Fibrosis Foundation President Rings Bell to Close New York Stock Exchange
Date:5/13/2008

Federal Realty Investment Trust invites Foundation to celebrate scientific advancements that have fueled longer life for people with CF

BETHESDA, Md., May 13 /PRNewswire-USNewswire/ -- To celebrate remarkable progress in treating cystic fibrosis -- a fatal genetic disease -- Federal Realty Investment Trust invited the Cystic Fibrosis Foundation to join the company as honored guests of the New York Stock Exchange (NYSE) today.

Life expectancy for people with CF has more than doubled in the past 25 years, as a result of scientific advances fueled by the Foundation. When the Foundation was established in 1955, few children with the disease lived to attend elementary school. Today, the median predicted age of survival for people with CF is 37 years.

In recognition of the Foundation's achievements and National CF Awareness Month, Robert J. Beall, Ph.D., president and CEO of the Foundation and Donald Wood, president and CEO of Federal Realty Investment Trust, rang the NYSE bell signaling the close of the market at 4:00 P.M today.

"We are pleased and honored to take part in this distinguished NYSE tradition," said Beall. "People with cystic fibrosis are living longer than ever, and we are excited about this tremendous progress. At the same time, there is much work to be done in the fight against this devastating disease."

To advance the search for a cure, the Foundation has built a "pipeline of promise" with more than 30 therapies in development for cystic fibrosis, and invested nearly $300 million in CF research in the biotech industry since 1998. For the first time in the history of the disease, the Foundation's pipeline has drugs under development that target the root causes of cystic fibrosis -- not just the symptoms. If successful, these therapies will add decades of life for people with CF.

Virtually every approved CF drug available today was made possible because of Foundation support. Since the 1980s, the Foundation has played an integral role in the development of Pulmozyme, TOBI, azithromycin and hypertonic saline for use as CF treatments.

"This is truly an exciting time for the CF community, with so many promising therapies in development," said Federal Realty Investment Trust president and CEO Donald Wood. "We are more passionate than ever about the Foundation's critical work to cure and control cystic fibrosis."

Federal Realty Investment Trust is an equity real estate investment trust specializing in the ownership, management, development, and redevelopment of high quality retail assets. Federal Realty is an S&P MidCap 400 company and its shares are traded on the NYSE under the symbol FRT.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the leading organization in the United States devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation has more than 80 chapters and branch offices throughout the country and supports and accredits a nationwide network of 115 care centers, which provide vital treatments and other CF resources to patients and families. For more information, visit http://www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ibuprofen can slow lung disease in children with cystic fibrosis, Canadian study shows
2. Anaheim to Host Worlds Largest Cystic Fibrosis Medical Meeting
3. AMRI and Cystic Fibrosis Foundation Launch Major Research Collaboration
4. Cystic Fibrosis Foundation Named Charitable Organization of the Year by USA Track & Field
5. Cystic Fibrosis foundation lays out new treatment guidelines
6. Experts Release New Cystic Fibrosis Guidelines
7. Lung Transplants May Not Help Most Cystic Fibrosis Children
8. Ibuprofen associated with slower lung function decline in children with cystic fibrosis
9. Ibuprofen Preserves Lung Function in Kids With Cystic Fibrosis
10. Montana Passes Newborn Screening Law for Cystic Fibrosis
11. Cystic Fibrosis Foundation reports upward trend for key health outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... ... 2016 , ... As a former television executive, owner Tal Rabinowitz knows how ... to decompress, Rabinowitz found herself drawn to a casual meditation class while working at ... life, implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, ...
(Date:2/12/2016)... ... 12, 2016 , ... Itopia, a leader in cloud services ... Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. This ... small and medium business (SMB) clients. , In recent years, BI ...
(Date:2/12/2016)... Arlington, TX (PRWEB) , ... February 12, 2016 , ... ... Worth, and other communities across eastern Texas, is launching a cooperative charity drive with ... and families. , Serving more than 50,000 individuals and families in need, the Tarrant ...
(Date:2/12/2016)... ... ... Donor Network West, the organ procurement organization that heals lives through organ ... Regional Medical Center. Under the collaboration, the first of its kind, specific organ donors ... certain time frame for donor families for the recovery of organs. , Organ ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... -- Eli Lilly and Company (NYSE: LLY ) today announced ... vitamin regimen patent would not presently be infringed by Actavis ... , Italy and Spain ... dextrose solution.  --> --> ... held that Lilly,s patent would be indirectly infringed by Actavis ...
(Date:2/12/2016)... 2016  Apellis Pharmaceuticals, Inc., today announced ... Series D preferred stock financing, co-led by ... Group and venBio Global Strategic Fund, joining ... Investment, and Epidarex Capital. The proceeds of the ... clinical trials in the Company,s ongoing complement ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary ... and future adoption patterns on the usage of liquid ... the following: - Timeframe of liquid biopsy ... ctDNA, cfDNA and Evs—by organization type - Sample inflow ... types: blood, saliva, stool, serum, and so on. - ...
Breaking Medicine Technology: